If you're searching for retatrutide dosage, you probably just saw the trial headlines — up to 28.7% body-weight loss in Phase 3 — and want two things: the real numbers behind those results, and whether there's a legitimate way to get the drug. Here is the honest version of both.
You can compare the 4 mg, 9 mg, and 12 mg trial paths side by side with our retatrutide dosage calculator.
What retatrutide actually is
Retatrutide (LY3437943) is an investigational once-weekly injectable from Eli Lilly — the first triple hormone receptor agonist to complete Phase 3. It activates GIP, GLP-1, and glucagon receptors. Semaglutide (Ozempic/Wegovy) hits GLP-1 only; tirzepatide (Mounjaro/Zepbound) hits GIP + GLP-1. The glucagon component is the differentiator: it's thought to increase energy expenditure and liver fat oxidation, though its isolated contribution to human weight loss remains mechanistically unproven. "Retatrutide" is not a brand name — no approved brand exists.
Why there is no official retatrutide dose
- Not FDA-approved for any indication. All core registrational trials — TRIUMPH-1 through TRIUMPH-4, plus the TRANSCEND-T2D-1 diabetes trial — have been completed. TRIUMPH-5, a head-to-head against tirzepatide, is still ongoing, with data expected in late 2026.
- Lilly announced on July 23, 2026 that it will file for FDA approval in early 2027. With standard review running 10–12 months (about 6 under priority review), approval is realistic no sooner than late 2027 to 2028.
- Compounding is illegal — retatrutide is in no FDA-approved product, so federal law bars pharmacies from making it.
- Powders sold online as "research chemicals" or "retatrutide peptide" are unregulated and illegal for human use. The FDA sent a warning letter to one seller in March 2026, and US poison-center exposures rose 265% in the first four months of 2026 versus the last four of 2025, per a Medscape report.
How the trials handled retatrutide dosing
Without turning this article into a protocol, here's what matters for reading any schedule:
- Every trial used once-weekly subcutaneous injections, starting low and stepping up at four-week intervals. The full climb to the highest target took roughly 16–20 weeks.
- Phase 3 tested three maintenance targets — 4 mg, 9 mg, and 12 mg — and added intermediate escalation steps the older Phase 2 protocol didn't have. That's why online charts disagree: many still show the outdated Phase 2 climb.
- All trial doses are in milligrams, not micrograms or syringe "units" — a common and dangerous forum error.
- The drug hangs around for about six days, peaks within 72 hours, and settles into a steady groove after a month of weekly injections — which is why once-a-week dosing works.
If the FDA approves retatrutide, the labeled schedule could differ from the trials. No one should start, stop, or dose any compound without a licensed clinician.
Using the retatrutide dosage calculator
A calculator can't tell you "your dose" — no approved dose exists. What it can do is visualize the trial protocols: the week-by-week escalation for each maintenance target, laid out side by side. Our retatrutide dosage calculator maps all three Phase 3 tracks; the peptide dosage calculator on our homepage covers the other compounds we track. Treat the output as a map of published trial data, nothing more.
What each dose delivered
Phase 2 — peer-reviewed. The 2023 New England Journal of Medicine trial (Jastreboff et al., 338 adults with obesity, 48 weeks) showed a clear dose-response — and weight loss had not plateaued at week 48:
| Dose | Mean weight change at 48 weeks |
|---|---|
| 1 mg | −8.7% |
| 4 mg | −17.1% |
| 8 mg | −22.8% |
| 12 mg | −24.2% |
| Placebo | −2.1% |
Phase 3 — topline only. Everything below comes from Lilly press releases and conference presentations; none of it has been peer-reviewed as of August 2026:
| Trial | Population | Key result (12 mg arm) | Reported |
|---|---|---|---|
| TRIUMPH-4 | Obesity + knee osteoarthritis | 28.7% weight loss at 68 weeks | Dec 11, 2025 |
| TRIUMPH-1 | Obesity + ≥1 comorbidity | 28.3% at 80 weeks; 30.3% at 104 weeks (BMI ≥35 subgroup) | May 21, 2026 |
| TRANSCEND-T2D-1 | Type 2 diabetes | −2.0% HbA1c; 16.8% weight loss at 40 weeks | June 2026 |
| TRIUMPH-2 | Obesity + type 2 diabetes | 20.8% weight loss | Jul 23, 2026 |
| TRIUMPH-3 | Obesity + cardiovascular disease | 22.6% weight loss | Jul 23, 2026 |
Two details keep these numbers honest. First, they're means: in TRIUMPH-1, 45.3% of participants on the highest dose lost ≥30% of body weight — meaning about 55% did not (65.3% got below a BMI of 30; 33.3% below 25). Second, lower targets still worked: the 4 mg arm produced roughly 19% mean weight loss in TRIUMPH-1.
Retatrutide side effects
Side effects were dose-dependent, peaked during escalation, and typically settled within four to six weeks at a stable dose. Gastrointestinal events dominated. In TRIUMPH-4, at the highest tested dose versus placebo: nausea affected about 43% of participants (10.7% on placebo), diarrhea 33% (13.4%), and vomiting 21% (0%). One signal is unusual for this drug class: dysesthesia — tingling or altered skin sensation — reported by roughly one in five participants at the highest dose, versus 0.7% on placebo.
In Phase 2 data, retatrutide also raised average heart rate by ~6.7 bpm at 12 mg — versus 2–4 bpm for tirzepatide and 1–4 bpm for semaglutide — consistent with its glucagon activity.
The unresolved risks matter more than the common ones: no safety data exist beyond 104 weeks, and pancreatitis, thyroid C-cell tumors (a rodent signal across the GLP-1 class), and long-term cardiovascular outcomes remain open questions. Seek urgent care for severe or persistent abdominal pain (especially radiating to the back), uncontrolled vomiting or signs of dehydration, a racing or pounding heartbeat, or any allergic-reaction symptoms. And the biggest immediate red flag isn't pharmacological: any "retatrutide" sold online today is an unregulated gray-market product.
What the internet gets wrong about retatrutide dosing
- "It's available now." It isn't — not by prescription, not compounded, not legally anywhere.
- "Retatrutide peptide" is gray-market phrasing designed to dodge drug law. Retatrutide is an investigational pharmaceutical, not a supplement.
- Charts mixing trial phases. If a schedule skips the intermediate steps added for Phase 3, it's built on the outdated Phase 2 protocol.
- Press-release results treated as settled science. All Phase 3 numbers are topline and not yet peer-reviewed.
- "28–30% loss for everyone." That's a trial mean under controlled conditions; most participants on the top dose didn't reach 30%.
- Unit confusion. Trial doses are milligrams. Forum posts converting to micrograms or syringe units are a common source of dangerous errors.
FAQ
What is the starting dose of retatrutide?
Every published trial protocol began with a low once-weekly dose and escalated at four-week intervals — the exact schedule is mapped step by step in the calculator. There is no approved starting dose, because the drug itself is unapproved.
How long does titration take?
Roughly 16–20 weeks to reach the highest maintenance target on the Phase 3 schedule — about four months of gradual escalation before maintenance begins.
Is a lower target like 4 mg or 9 mg enough?
Both were tested as maintenance doses and produced meaningful loss — the 4 mg arm averaged about 19% in TRIUMPH-1. Efficacy and side effects both scale with dose.
What happens if you miss a dose?
There is no official missed-dose rule — the drug is unapproved, and trial protocols didn't publish one. With a ~6-day half-life, levels fall slowly, but this is a question for a clinician, not a forum.
How does retatrutide dosing compare with tirzepatide?
Different molecules, different schedules — and tirzepatide is actually approved (Mounjaro/Zepbound). Our tirzepatide dosage calculator shows its labeled titration for contrast.
When can I get a real prescription?
Lilly plans to file in early 2027; the earliest realistic approval window is late 2027 to 2028. Until then, anything sold as retatrutide for human use is illegal and unverified.